• Explore /
  • Poster
  • / KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

Abstract Poster

Authors

null

Matt D. Galsky

Icahn School of Medicine at Mount Sinai, New York, NY

Matt D. Galsky , Andrea Necchi , Neal D. Shore , Elizabeth R. Plimack , Calvin Jia , Eric Sbar , Blanca Homet Moreno , Johannes Alfred Witjes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03924895

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr TPS507)

DOI

10.1200/JCO.2021.39.6_suppl.TPS507

Abstract #

TPS507

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Matt D. Galsky

First Author: Christopher J. Hoimes

First Author: Thomas W. Flaig

First Author: Christopher J. Hoimes